Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2022
Nuvalent appoints Emily Drabant Conley to its board
Nuvalent announced the appointment of Emily Drabant Conley, CEO of Federation Bio, to its Board of Directors.
2021
Nuvalent reports third-quarter 2021 financial results
Nuvalent reported its third-quarter 2021 financial results and pipeline progress.
2021
FDA clears Nuvalent’s NVL-520 IND application
The U.S. FDA cleared Nuvalent’s Investigational New Drug application for NVL-520, enabling the company to proceed toward clinical testing. Nuvalent said it was preparing to initiate the Phase 1 portion of a global Phase 1/2 trial in the second half of 2021.
2021
Nuvalent appoints chief legal officer and board director
Nuvalent reported appointing Deborah Miller as chief legal officer and Sapna Srivastava to its board of directors.
2021
Nuvalent completes $190.6 million IPO
Nuvalent completed its upsized initial public offering, selling 11,212,500 shares at $17.00 per share and raising approximately $190.6 million in gross proceeds before expenses.